Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus CEPHALEXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus CEPHALEXIN.
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER vs CEPHALEXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and disrupting cell wall cross-linking, leading to cell lysis and death.
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
Oral: 250-1000 mg every 6 hours; maximum 4 g/day.
None Documented
None Documented
Clinical Note
moderateCephalexin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Cephalexin."
Clinical Note
moderateCephalexin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cephalexin."
Clinical Note
moderateCephalexin + Sulfisoxazole
Terminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment.
0.5-1.2 hours in normal renal function; prolonged to 5-30 hours in severe renal impairment (CrCl <10 mL/min)
Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The metabolism of Sulfisoxazole can be decreased when combined with Cephalexin."